European Journal of Cancer, Supplement
European Journal of Cancer, Supplement is a journal indexed in SJR in Oncology and Cancer Research with an H index of 30. It is an CC BY-NC-ND Journal with a Single blind Peer Review review system, and It has a price of 2700 €. The scope of the journal is focused on cancer, translational oncology, clinical oncology, cancer epidemiology, cancer prevention. It has an SJR impact factor of 0,428 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,428.
Metrics
Scimago and CountryOfPapers database fields
SJR Impact
0,428
H-index
30
Docs (year)
0
Docs 3y
3
Total refs
0
Cites 3y
2
Citable 3y
2
Cites/Doc 2y
0
Ref/Doc
0.0
Immediate OA
2700 €
Embargoed OA
NPD
Non OA / Submission
- €
Name good journals. Call out predatory ones.
Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.
Researcher reviews
Best articles by citations
112 Head and neck reconstruction in oncology
View more98 Neoadjuvant chemotherapy plus radiotherapy versus radiotherapy alone and the quality of radiation therapy in the treatment of locally advanced nasopharyngeal carcinomas
View more21 Histologic type of local recurrence and prognostic significance in breast conservation vs. mastectomy in invasive breast cancer: A 20-year update of a randomized trial
View more20 The effect of treatment interruptions in the postoperative irradiation of breast cancer
View more2 Supportive care in cancer - the ultimate challenge in modern multiprofessional oncology
View more19 Fractionation sensitivity of breast cancer. Results of a randomised trial
View more18 Impact of early start of adjuvant chemotherapy in breast cancer in Denmark
View more17 Can danish breast cancer patients by early diagnosis achieve the same survival as observed in Sweden? A study in screened and non-screened Danish and Swedish populations
View more16 A combined analysis of three European audits of primary breast cancer management
View more15 Monotoring cancer occurrence and outcome in Europe in the 21st century
View more14 The status of bone marrow transplant clinical trials
View more13 The biology of paediatric cancer
View more12 Immunotherapy of cancer - T-cell therapies
View more1 The clinicopathological and molecular features of MALT lymphoma
View more111 Early stage oral cavity squamous cell carcinoma
View more110 Cisplatin + vinorelbine in recurrent salivary gland malignancies: final report on 42 cases
View more11 Targeting host-tumour interactions in myeloma therapies
View more109 Cisplatin-DNA adduct measurements in head and neck cancer patients treated by chemoradiotherapy
View more108 Stereotactic radiotherapy (SRT) plus external radiotherapy as radical treatment in nasopharyngeal carcinoma (NPC) with first local recurrence (LR), Queen Elizabeth hospital experience
View more107 Phase II continuous 7 days per week irradiation concomitantly with chemotherapy in advanced head and neck tumors treatment
View more105 Glottic cancer and the impact of the duration of symptoms
View more104 Oral cavity verrucous carcinoma
View more102 Late normal tissue sequelae and performance status with brachytherapy or surgery in tonsillar fossa and soft palate tumors. Can we be more selective?
View more100 Radiotherapy for oropharyngeal cancer. Results from 1998 to 2001 with emphasis on the correlation between treatment technique and side effects
View more